Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Aug 16, 2017 at 10:55 AM ET
2017 Wedbush PacGrow Healthcare Conference
Aug 3, 2017 at 1:30 PM PT
Arbutus Biopharma Corporation 2017 Second Quarter Financial Results and Corporate Update